Prostate cancer is a disease associated with androgens.
It has been hypothesized that reducing the conversion of testosterone (T) to dihydrotestosterone (DHT) in the prostate by the use of the drug finasteride, a 5alpha-reductase inhibitor, will reduce the incidence of prostate cancer.
We investigated the chemopreventive potential of finasteride by evaluating its effect on the prostate gland of men with elevated serum prostate-specific antigen (PSA).
Fifty-two men with elevated PSA and prostate sextant biopsies negative for cancer were randomized to receive finasteride 5 mg day-1 (27 patients) or no medication (25 patients) for 12 months and were rebiopsied at 12 months.
The biopsies were evaluated for the presence of cancer, the proportion of glandular and hyperplastic tissue, and the presence of high-grade prostatic intraepithelial neoplasia (PIN).
Epithelial proliferation was assessed in the prestudy and 12-month biopsies by immunohistochemistry using antibody to proliferating cell nuclear antigen (PCNA).
Serum blood samples were drawn at baseline and after 1,3,6 and 12 months of study.
In the control group, serum levels of PSA and T were unchanged throughout the 12 months.
In the finasteride group, PSA decreased 48% (P<0.001), DHT decreased 67% (P<0.001) and T increased 21% (P<0.001).
Histological evaluation of prestudy and 12-month biopsy specimens revealed that the finasteride group had a 30% reduction in the percentage of hyperplastic epithelial tissue. (...)
Mots-clés Pascal : Carcinome, Prostate, Antigène spécifique tumeur, Facteur risque, Epidémiologie, Finastéride, Anticancéreux, Inhibiteur enzyme, Reductase, Oxidoreductases, Enzyme, Prévention, Chimioprophylaxie, Etats Unis, Amérique du Nord, Amérique, Homme, Azastéroïde, Tumeur maligne, Prostate pathologie, Appareil urinaire pathologie, Appareil génital mâle pathologie
Mots-clés Pascal anglais : Carcinoma, Prostate, Tumor specific antigen, Risk factor, Epidemiology, Finasteride, Antineoplastic agent, Enzyme inhibitor, Reductase, Oxidoreductases, Enzyme, Prevention, Chemoprophylaxis, United States, North America, America, Human, Azasteroid, Malignant tumor, Prostate disease, Urinary system disease, Male genital diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0372047
Code Inist : 002B14D02. Création : 25/01/1999.